Follow AstraZeneca to never miss an important update.
A committee of the European Medicines Agency, the group that evaluates new medicines for the European Union, gave a positive opinion on baxdrostat. This drug is designed to treat hypertension, or high blood pressure, specifically for patients who have not found relief with existing treatments.
While AstraZeneca is increasingly focused on high-margin cancer and rare disease drugs, this recommendation helps round out its heart and metabolism portfolio. This backing is a major step toward final marketing approval in Europe, which would allow the company to launch the treatment in a large market where many patients still struggle to control their blood pressure levels.
Source: Reuters
AstraZeneca has acquired Omniose, a small biotechnology company it has worked with for three years. The deal brings Omniose's bioconjugation platform into AstraZeneca's infectious disease unit. This technology helps attach sugars to proteins, a key step in creating vaccines that help the immune system recognize and fight specific bacteria.
While the price was not disclosed, the move fits the company's strategy of buying specialized technology rather than just finished drugs. By owning the platform itself, AstraZeneca can develop a wider range of vaccines more efficiently. This is a small but logical addition to its research arm that strengthens its ability to build new treatments from the ground up.
Source: Business Wire
AstraZeneca has reportedly made a $10 billion offer to acquire Rhythm Pharmaceuticals. This move would expand its portfolio of treatments for rare diseases, a high-value area where the company is already a leader through its Alexion division.
Rare disease drugs are often more profitable because they treat conditions with few other options and face less competition. While $10 billion is a large sum, it fits the company's strategy of using its cash to buy new technology and reach its goal of $80 billion in annual revenue by 2030.
Source: WSJ
After AstraZeneca reported its October results, we updated our profit projections to include a new two billion dollar restructuring program and its expected annual savings. We have added the company's two billion dollar investment in Summit Therapeutics to our model as a new bet on cancer drug technology. We also raised our expectations for how much of every dollar of sales the company keeps as a result of its more profitable rare disease treatments. We continue to track whether revenue from cancer drugs can grow faster than 15% each year.
AstraZeneca reported third-quarter sales of about 16.2 billion dollars, coming in ahead of the 16 billion dollars analysts expected. Earnings per share reached $2.79, beating the average estimate of $2.60. The results were fueled by strong demand for its oncology portfolio, which includes drugs that treat specific types of lung and breast cancer.
This performance supports the company's shift toward specialty medicines that are harder for competitors to copy. Net profit rose to 3.12 billion dollars from roughly 2.5 billion dollars a year ago. By moving away from mass-market primary care and into high-margin cancer and rare disease therapies, the company is building a more resilient business that is less vulnerable to generic competition.
See the full quarter, and how our tracked metrics did
Source: Company earnings report
Management has cleared its own profit targets for eight straight quarters. This perfect run shows they have a firm handle on their costs even while spending heavily on new drug research.
| Expectation | |
|---|---|
| EPS | $2.32 |
| Revenue | $16.61B |
Follow AstraZeneca to get the latest and most important updates.
Follow AZN